PERINDOPRIL/INDAPAMIDE TABLET

Riik: Kanada

keel: inglise

Allikas: Health Canada

Toimeaine:

INDAPAMIDE; PERINDOPRIL ERBUMINE

Saadav alates:

SANIS HEALTH INC

ATC kood:

C09BA04

INN (Rahvusvaheline Nimetus):

PERINDOPRIL AND DIURETICS

Annus:

0.625MG; 2MG

Ravimvorm:

TABLET

Koostis:

INDAPAMIDE 0.625MG; PERINDOPRIL ERBUMINE 2MG

Manustamisviis:

ORAL

Ühikuid pakis:

100

Retsepti tüüp:

Prescription

Terapeutiline ala:

ANGIOTENSIN-CONVERTING ENZYME INHIBITORS

Toote kokkuvõte:

Active ingredient group (AIG) number: 0248401002; AHFS:

Volitamisolek:

APPROVED

Loa andmise kuupäev:

2021-08-30

Toote omadused

1
PRODUCT MONOGRAPH
PR
PERINDOPRIL/INDAPAMIDE
Perindopril Erbumine and Indapamide Tablets
2 mg/0.625 mg, 4 mg/1.25 mg and 8 mg/2.5 mg
Angiotensin converting enzyme inhibitor / Diuretic
Sanis Health Inc.
1 President’s Choice Circle
Brampton, Ontario
L6Y 5S5
Date of Revision:
August 27, 2021
Control No.: 254247
2
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION SUMMARY
....................................... 3
SUMMARY PRODUCT INFORMATION
....................................................................................
3
INDICATIONS AND CLINICAL USE
..........................................................................................
3
CONTRAINDICATIONS
...............................................................................................................
4
WARNINGS AND PRECAUTIONS
..............................................................................................
5
ADVERSE REACTIONS
..............................................................................................................
15
DRUG INTERACTIONS
..............................................................................................................
21
DOSAGE AND ADMINISTRATION
..........................................................................................
28
OVERDOSAGE
.............................................................................................................................
30
ACTION AND CLINICAL PHARMACOLOGY
........................................................................
30
STORAGE AND STABILITY
......................................................................................................
35
DOSAGE FORMS, COMPOSITION AND PACKAGING
.......................................................... 35
PART II: SCIENTIFIC INFORMATION
...................................................................................
36
PHARMACEUTICAL INFORMATION
......................................................................................
36
CLINICAL TRIALS
...................